|By Marketwired .||
|June 18, 2014 02:38 PM EDT||
LOS ANGELES, CA -- (Marketwired) -- 06/18/14 -- Verde Science, Inc. (OTCQB: VRCI) is pleased to announce the appointment of Bradley J. Dixon, J.D. to the Board of Directors. Mr. Dixon is a trial attorney and partner in the Boise, Idaho office of Stoel Rives, LLP, which has locations throughout the northwest and California. Mr. Dixon is ranked by Chambers and Partners and was named in the 2013 Mountain States Directory of Super Lawyers. He has a wide range of litigation experience, which includes Agricultural, Natural Resources, Labor and Employment, and Product Liability cases. Mr. Dixon's trial experience representing clients through complex litigation on a broad range of disputes including complex commercial litigation, employment, insurance coverage, products liability, title insurance, foreclosure and bankruptcy trial practice, as well his governmental affairs service experience meshes well with the future needs of Verde Science.
As Verde Science has developed into its current complex structure, it became apparent that legal oversight from an experienced attorney such as Mr. Dixon was a requirement. The business now consists of multiple interconnected facets, which include the scientific and engineering sides of the aeroponics and hydroponics marijuana grow business, management consulting services, capital funding services, and basic research and development into future prescription drugs.
Ken Berscht, CEO of Verde Science, stated, "I am very pleased to have Brad on our Board of Directors as he brings a tremendous amount of relevant experience to our company. With his broad legal background he can help guide us through the challenges of this business as it matures and spreads to more and more jurisdictions. Brad broadens the knowledge base of our board which will help position Verde Science as dominant force in the medical marijuana market."
About Verde Science
Verde Science plans to take an all-encompassing, integrated public health approach to medical marijuana with a focus on becoming the leader in providing services to legal, licensed cannabis cultivators and dispensaries and their patient community. Verde's focus, in collaboration with its partners, is on deploying an advanced array of technical services to foster an integrated health care model in legal jurisdictions in North America.
The Company provides a variety of products and services to its clients by using best practices to ensure the best quality of product, produced with focus on cost control and legal compliance. Verde Science is meticulous, measured and diligent with an absolute focus on compliance while offering growers and their patient community unsurpassed, fully integrated, holistic health care products and programs.
Verde Science is one of the initial corporate players in the medical marijuana industry providing sophistication, controls, standards and innovation. The company has and will continue to assemble a highly experienced team that will deploy state-of-the-art technology and a superior methodology to enter and take meaningful market share that can be repeated and expanded as more and more jurisdictions adopt legal use of cannabis products to address health care issues.
Safe Harbor Statements
Certain information contained in this news release constitutes "forward-looking statements" as such term is used in applicable United States and Canadian laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates", "intends" or "believes", or that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur", or "be achieved". Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this news release can be found in the Company's filings with the SEC. Such risks and other factors include, among others, the ability to locate and acquire suitable interests in alternative medicine manufacturing operations on terms acceptable to the Company, the availability of financing on acceptable terms, accidents, labor disputes, acts of God and other risks of the alternative medicine industry including, without limitation, delays in obtaining governmental approvals or permits, title disputes or claims limitations on insurance coverage. The Company believes that the expectations reflected in the forward-looking statements included in this news release are reasonable; however, no assurance can be given that these expectations will prove to be correct, and such forward-looking statements should not be unduly relied upon. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
For further information please contact:
Torrey Hills Capital
Jim MacDonald/Clay Chase